News | August 02, 2025
Sun Pharmaceutical Q1 FY26 consolidated PAT falls by 20% to Rs. 2,278 Cr
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
India Formulation sales accounted for 34.2% of total consolidated sales for the quarter
Dilip Shanghvi to continue as the Executive Chairman of the Board
Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
This Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability
These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
GL0034 administered once-weekly confirmed clinically meaningful weight loss and improved glucometabolic parameters over a 4-week treatment period in individuals with obesity
Combined entity is better positioned to compete in increasingly competitive generics industry
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
Subscribe To Our Newsletter & Stay Updated
